Magazine Article | April 1, 2022

Thinking Differently About Rare Disease Therapies

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

In the 1990s, before large swaths of the biopharmaceutical industry turned toward rare disease drug development, Dr. Emil Kakkis, an assistant professor at Harbor-UCLA, began developing an enzyme to treat an exceedingly rare disease, known as mucopolysaccharidosis, or MPS I. It was the beginning of a journey that would ultimately lead to the founding of a rare and ultra-rare disease company — Ultragenyx — and the creation of a nonprofit patient advocacy organization — the EveryLife Foundation for Rare Diseases.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: